$3.70
+0.00 (+0.00%)
Open$3.75
Previous Close$3.70
Day High$3.92
Day Low$3.64
52W High$23.43
52W Low$2.90
Volume—
Avg Volume79.7K
Market Cap26.64M
P/E Ratio—
EPS$-7.19
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+218.1% upside
Current
$3.70
$3.70
Target
$11.77
$11.77
$8.46
$11.77 avg
$14.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.06M | 37.98M | 31.57M |
| Net Income | -51,784,967 | -146,792,032 | 932.2K |
| Profit Margin | -429.4% | -408.0% | 3.0% |
| EBITDA | -34,358,926 | -102,806,235 | 1.58M |
| Free Cash Flow | — | — | 483.5K |
| Rev Growth | -68.3% | -68.3% | +6.0% |
| Debt/Equity | 0.19 | 0.19 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |